California biologics regulations.

Who may administer PRP, exosomes and stem cells in California, and which agencies to check.

A physician at a desk reading regulatory documents

Who may administer biologics in California?

Only licensed medical doctors (MDs) and doctors of osteopathic medicine (DOs) in California are permitted to administer stem cell therapies. Nurse practitioners and physician assistants may support in administering these treatments under direct supervision of a licensed physician.

Official sources

California compliance guide.

FDA Compliance

The U.S. Food and Drug Administration (FDA) regulates human cells, tissues, and cellular- and tissue-based products (HCT/Ps) under Section 361 of the Public Health Service Act and 21 CFR Part 1271. California providers must adhere to these federal guidelines, which detail requirements on sourcing, processing, and labeling of biologic materials, as well as how and when Investigational New Drug (IND) applications may be required.

California State Regulations

California enforces additional regulations through the California Department of Public Health (CDPH), with oversight on biologics that may involve stem cell and tissue-based therapies. Clinics are encouraged to review state-specific guidelines for stem cell treatments to ensure compliance with local standards, including patient safety and ethical administration practices.

Provider Qualifications

Only licensed medical doctors (MDs) and doctors of osteopathic medicine (DOs) in California are permitted to administer stem cell therapies. To learn more about licensure requirements, visit the Medical Board of California. Nurse practitioners and physician assistants may support in administering these treatments under direct supervision of a licensed physician.

Patient Informed Consent

Key Consent Elements:

California requires explicit patient consent that covers the experimental nature of biologics and potential risks. A compliant informed consent form should include:

  • A detailed explanation of the procedure, including risks and benefits.
  • Notification of the experimental or investigational nature of certain treatments, as biologics may not be FDA-approved for certain uses.
  • Patient rights to discontinue treatment at any time without penalty.

Additional Compliance Steps

Pre-Treatment and Post-Treatment Protocols

Clinics should establish clear pre-treatment and post-treatment protocols, focusing on patient eligibility, follow-up visits, and outcome monitoring to ensure safety and regulatory compliance.

Standard Operating Procedures (SOPs)

Documented SOPs are essential for compliant administration, storage, and handling of biologic materials. They ensure consistency and adherence to both federal and state regulations.

Medical Liability Insurance

Clinics are encouraged to obtain adequate medical liability insurance that covers biologics and stem cell treatments to mitigate potential legal risks.

Marketing Compliance

Advertising for biologic treatments in California must adhere to FDA marketing regulations and cannot mislead patients regarding the efficacy or safety of treatments. Consult the FDA’s guidance on healthcare advertising to ensure all marketing efforts are compliant.

This guide is a general summary to help clinics understand compliance requirements for biologics in California. It is not legal advice. Regulations change; consult legal counsel and the agencies above before acting on it.

California: common questions.

Who can administer stem cells, PRP and exosomes in California?
Only licensed medical doctors (MDs) and doctors of osteopathic medicine (DOs) in California are permitted to administer stem cell therapies. Nurse practitioners and physician assistants may support in administering these treatments under direct supervision of a licensed physician. This is a general summary, not legal advice. Confirm with the state board.
Are stem cell and exosome therapies FDA-approved in California?
FDA rules are federal, so they apply in California as everywhere else. Exosome and stem cell therapies are not FDA-approved for therapeutic use, and PRP applications are considered off-label.
Do I need an IRB-approved study to offer biologics in California?
Investigational treatment belongs inside a reviewed study with proper informed consent. IRB review is not FDA authorisation: culture-expanded and other more-than-minimally-manipulated cell products generally need an IND before use in people.
How do I start offering biologics in California?
Start with the live webinar, then a discovery call and live training. After that we verify your California licence, protocol, product sourcing, consent process and advertising before you are listed for patient inquiries.

Practising in California? Start with the webinar.

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.